EUVIMEDEUVIMED entdecken
Crossref

Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC

Aya Shiba-Ishii, Takayuki Isagawa, Toshihiro Shiozawa, Naoko Mato, Tomoki Nakagawa, Yurika Takada, Kanon Hirai, Jeongmin Hong, Anri Saitoh, Norihiko Takeda, Toshiro Niki, Yoshinori Murakami und 1 weitere

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2024

DOI: 10.1016/j.bbadis.2024.167249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024. Verfasst von Aya Shiba-Ishii und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-ret, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RET fusion is an oncogenic driver in 1-2 % of patients with non-small cell lung cancer (NSCLC). Although RET-positive tumors have been treated with multikinase inhibitors such as vandetanib or RET-selective inhibitors, ultimately resistance to them develops. Here we established vandetanib resistance (VR) clones from LC-2/ad cells harboring CCDC6-RET fusion and explored the molecular mechanism of the resistance. Each VR clone had a distinct phenotype, implying they had acquired resistance via different mechanisms. Consistently, whole exome-seq and RNA-seq revealed that the VR clones had unique mutational signatures and expression profiles, and shared only a few common remarkable events. AXL and IGF-1R were activated as bypass pathway in different VR clones, and sensitive to a combination of RET and AXL inhibitors or IGF-1R inhibitors, respectively. SMARCA4 loss was also found in a particular VR clone and 55 % of post-TKI lung tumor tissues, being correlated with higher sensitivity to SMARCA4/SMARCA2 dual inhibition and shorter PFS after subsequent treatments. Finally, we detected an increased number of damaged mitochondria in one VR clone, which conferred sensitivity to mitochondrial electron transfer chain inhibitors. Increased mitochondria were also observed in post-TKI biopsy specimens in 13/20 cases of NSCLC, suggesting a potential strategy targeting mitochondria to treat resistant tumors. Our data propose new promising therapeutic options to combat resistance to RET inhibitors in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins c-retDrug Resistance, NeoplasmLung NeoplasmsMitochondriaPiperidinesProtein Kinase InhibitorsHumansCell Line, TumorQuinazolinesTranscription FactorsSignal TransductionOncogene Proteins, FusionDNA HelicasesCytoskeletal Proteins

Stichwörter der Autor:innen

Drug resistanceLung cancerMitochondriaNSCLCTargeted therapiesVandetanib

Substanzen

Proto-Oncogene Proteins c-retRET protein, humanPiperidinesProtein Kinase InhibitorsvandetanibQuinazolinesCCDC6 protein, humanTranscription FactorsOncogene Proteins, FusionDNA Helicases

Autor:innen und Institutionen

  • Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Center for Data Science, Jichi Medical University, Tochigi, Japan.
  • Department of Respiratory Medicine, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Ibaraki, Japan.
  • Department of Pathology, University of Tsukuba Hospital, Ibaraki, Japan.
  • Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Shiba-Ishii, A., Isagawa, T., Shiozawa, T., Mato, N., Nakagawa, T., Takada, Y., Hirai, K., Hong, J., Saitoh, A., Takeda, N., Niki, T., Murakami, Y., & Matsubara, D. (2024). Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2024.167249

Vancouver

Shiba-Ishii A, Isagawa T, Shiozawa T, Mato N, Nakagawa T, Takada Y, et al. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024. doi:10.1016/j.bbadis.2024.167249

BibTeX
@article{ShibaIshii2024,
  author = {Shiba-Ishii, Aya and Isagawa, Takayuki and Shiozawa, Toshihiro and Mato, Naoko and Nakagawa, Tomoki and Takada, Yurika and Hirai, Kanon and Hong, Jeongmin and Saitoh, Anri and Takeda, Norihiko and Niki, Toshiro and Murakami, Yoshinori and Matsubara, Daisuke},
  title = {Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC},
  journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
  year = {2024},
  doi = {10.1016/j.bbadis.2024.167249}
}
Kostenlos starten →